# NeuroTracker Presentation - Text Document

## Slide 1: Title Slide

**nothing artificial**
ENHANCING HUMANS.™

Brand: NeuroTracker

---

## Slide 2: Mission & Philosophy

### Quote
"Creating Better Humans will always be more important than creating smarter machines"
— Gary Kasparov, World chess champion

### Problem
In the age of AI, the limiting factor is no longer machines—It's **Cognition**.

### Opportunity
**Cognition** is the next frontier yet to be scaled.

---

## Slide 3: Cognition at Scale - Scientific Results

**Cognition at Scale. Based in Science.**

NeuroTracker targets cognitive processes such as working memory, attention, processing speed, and cognitive flexibility.

### Performance Improvements (Scientific studies show - references in appendix)

**PERIPHERAL VISION: 34%**
- Faster, better, safer in sports, driving, less accidents

**FATIGUE RESILIENCE: 99%**
- Fatigue resilience increased 99%

**COGNITIVE AGILITY: 34%**
- Stronger, resilient, more adaptable to change

**PERCEPTION: 52%**
- Smarter, faster, better comprehension and communication

**FOCUS: 40%**
- Increase productivity, academic and executive performance

**DECISION MAKING: 40%**
- Decision errors reduced 40%

---

## Slide 4: What is NeuroTracker?

A **6 minute** visual exercise to measure and improve **Cognitive Performance**

### Setup
NeuroTracker App can be downloaded on **any laptop, PC or tablet**. Use **optional** 3D glasses to accelerate results.

### Train
Track the highlighted objects as they move in 3D. The **patented algorithm** adapts automatically to your performance to maintain an optimal training threshold.

### Repeat
Complete **3 sessions** to **measure** baseline and a minimum of **15 sessions** to start to build measurable cognitive **improvement**.

**Key Feature:** Track and identify the targets

---

## Slide 5: NeuroTracker in Action - Real-World Applications

NeuroTracker is used across various professional and amateur contexts:

### Professional Sports
- Professional Race-car Driver
- Takuma Koga - NASCAR Driver
- Professional Ice-hockey player
- Professional eSports gamer
- Quarterback Matt Ryan
- Professional Basketball player
- Amateur Cyclists

### Elite Athletes Featured in Documentaries
- Pierre-Emerick Aubameyang (Olympique Marseille) - Canal+ Documentary
- Trent Alexander Arnold (Real Madrid) - RedBull TV Documentary
- Agon Movie by Giulio Bertelli (PRADA)

### Teams & Organizations
- Ukrainian Olympic Team

### Educational & Medical Applications
- NeuroTracker at school
- Concussion Rehabilitation Patient

---

## Slide 6: Data Driven and Embeddable

### Key Value Propositions

**Data Generation:**
- NeuroTracker is generating unique Cognitive data
- Useful for Pharma, Healthcare, AI and LLMs

**Integration Capabilities:**
- Can be used as an Adjunct to other products such as drugs, nutraceuticals, wearables or tech devices
- Has a robust API and can be embedded into multiple devices

### Technology Partners & Integrations
- Gemini
- Anthropic
- Rok
- Scale
- Pfizer
- UCB
- Abbvie
- Abbott
- SnapChat Spectacles
- Apple Vision Pro
- Fitbit
- Meta
- Google AR

### Compatible Devices
Google XR, SnapChat spectacles, Meta glasses, Apple Vision Pro, Fitbit, Apple Watch, Pixel, and Samsung Galaxy

---

## Slide 7: Established Global Customers

### Market Reach
- **1000+** Business installations
- **57+** Countries

### Customer Portfolio

**Professional Sports Teams:**
- Olympique Lyonnais (Soccer)
- Manchester United (Soccer)
- Club América (Soccer)
- Boston Red Sox (Baseball)
- Los Angeles Lakers (Basketball)
- Atlanta Falcons (NFL)
- Jacksonville Jaguars (NFL)
- Washington Nationals (Baseball)
- Washington Capitals (Hockey)
- Borussia Dortmund (Soccer)

**Motorsports:**
- Alpine F1 Team
- RedBull Racing Formula One Team

**Military & Government:**
- U.S. Air Force
- Air Force
- NASA

**Healthcare & Research:**
- Bayer
- UCB
- Swiss Medical Network
- Stanford Health
- Berkeley University of California

### Media Coverage - As Seen On:
- Fox News
- Wired
- CBS News
- The New York Times
- BBC
- CNBC

---

## Slide 8: Research & Scientific Validation

### 120+ Studies & Trials on NeuroTracker across many different populations

**120+ Peer-Reviewed Studies & Publications**

### Featured Studies by Year:

**2017:**
- **3D Multiple Object Tracking Boosts Working Memory Span: Implications for Cognitive Training in Military Populations**
  - A 3-hour NeuroTracker training intervention transfers to significant improvements across 3 types working memory assessments in military personnel

**2024:**
- **Transferability of Multiple Object Tracking Skill Training to Professional Baseball Players' Hitting Performance**
  - NeuroTracker training across a professional baseball season transfers to improvements in hitting performance for curveballs and sliders

**2022:**
- **Effect of 3D-Multiple Object Tracking Training on Manual Dexterity in Elderly Adults with Dementia and Mild Cognitive Impairment**
  - A short NeuroTracker training intervention significantly improves fine motor-skills in elderly adults diagnosed with cognitive impairments

**2020:**
- **Effects of 3D-Multiple Object Tracking on Reaction Time Performance in High-Performance Varsity Swimmers**
  - A short NeuroTracker training intervention significantly improves off-the-block reaction times for elite collegiate swimmers

**2016:**
- **3D-Multiple Object Tracking task performance improves passing decision-making accuracy in soccer players**
  - 3-hours of NeuroTracker training improves the passing decision-making accuracy of collegiate soccer athletes by 15% in competitive play

**2016:**
- **Enhancing Cognitive Function Using Perceptual-Cognitive Training**
  - Comprehensive pre-post neuropsychological and qEEG neuroimaging assessments reveal robust and wide gains in college students' cognitive abilities

**2023:**
- **Nutrition, lifestyle, and cognitive performance in esport athletes**
  - NeuroTracker baselines and learning rates correlate with the dietary intake and sleep quality of esports athletes, revealing significant effects on cognition

**2019:**
- **Dimensional Multiple Object Tracking Training Can Enhance Selective Attention, Psychomotor Speed, and Cognitive Flexibility in Healthy Older Adults**
  - Older adults show significant cognitive gains across a battery of neuropsychological assessments with a short NeuroTracker intervention

**Key Finding:** NeuroTracker has shown to improve **far-transfer**.

*References in Appendix*

---

## Slide 9: How Did We Get Here? - Company History & Credentials

### Research Foundation
- **20+** Years of Neuroscience Research
- **120+** Peer-Reviewed Studies & Publications
- **51** Issued & Pending Patents

### Financial Backing
- **$67M** Total Research & Commercial Funding
- **$27M** in Government Grants

### Market Penetration
- **1000+** Business Installations

### Company Timeline (2001 - Today)

**2001:**
- Born out of Faubert Lab, University of Montreal

**2016:**
- IP Tech Transfer & Manchester United first commercial implementation
- Organic growth of the on-prem "solution": Achieved 200+ installs

**2021:**
- Launch of B2B Cloud SaaS platform

**2023:**
- Acquisition of FDA & ISO Certified Company Nile AI & UCB Pharma investment

**2024:**
- Launch of B2C Cloud SaaS platform

**2025:**
- $59M licensing deal in MENA & GCC expansion

**Today:**
- Launch of Healthcare Division

---

## Slide 10: Medical Applications - Cognitive Functions & Disorders

### Neurotracker Targets Multiple Cognitive Functions and Networks Relevant to Many Medical Disorders

### Cognitive Functions Targeted:
- Working Memory
- Cognitive Flexibility
- Selective Attention
- Sustained Attention
- Divided Attention
- Inhibition
- Inhibitory Control
- Processing Speed
- Short-term Memory

### Medical Disorders & Conditions:

**Neurodegenerative:**
- Dementia
- Mild Cognitive Impairment
- Multiple Sclerosis

**Neurodevelopmental:**
- ADHD
- Autism Spectrum Disorder

**Neurotraumatic:**
- Concussion
- Traumatic Brain Injury
- Chronic Traumatic Encephalopathy

**Psychiatric:**
- Depression
- Anxiety Disorders
- Schizophrenia
- Bipolar Disorder

**Infection:**
- Meningitis
- HIV/AIDS
- Sepsis
- Covid-19

**Vascular:**
- Stroke
- Transient Ischemic Attack

---

## Slide 11: NeuroTracker Expansion

### Now: Performance & Wellness

**Current Market Segments:**
- Military
- Sports
- eSports
- Education
- Corporate
- Wellness Centers
- Senior living Centers

### Next: Health & Healthcare

**Healthcare Focus Areas:**
- Digital Biomarkers
- Digital Diagnostics
- Digital Therapeutics

**Breakthrough Research:**
Recent breakthrough clinical trial opens door to transform neurocognitive health through digital neurobiomarkers and neurotherapeutics

*SMARTBRAIN TRIAL - Reference in Appendix*

---

## Slide 12: The Digital Healthcare Market - A Timely Opportunity

### Digital therapeutics are now investable
Regulatory and reimbursement frameworks are mature, enabling scalable adoption.

### Platform foundation accelerates growth
Years of validated performance data and clinical research reduce execution risk.

### Immediate, De-Risked Entry Via Digital Biomarkers
Non-regulated exploratory use generates near-term revenue and clinical adoption.

### Staged path to regulated digital therapeutic
Supports long-term revenue, reimbursement, and healthcare integration.

*Source: Ernst & Young, Digital Therapeutics Market Analysis 2025*

---

## Slide 13: Healthcare Division - Development Plan

### Market Opportunity: $400B+

### Product Development Timeline (Years 1-5)

**ADHD Product Lines:**
- ADHD DBx (Digital Biomarker)
- ADHD DDx (Digital Diagnostic)
- ADHD DTx (Digital Therapeutic)

**TBI Product Lines:**
- TBI DBx (Digital Biomarker)
- TBI DDx (Digital Diagnostic)
- TBI DTx (Digital Therapeutic)

**MCI Product Lines:**
- MCI DBx (Digital Biomarker)
- MCI DDx (Digital Diagnostic)
- MCI DTx (Digital Therapeutic)

### Target Markets:
USA, Canada, EU, Japan

### Key Points:

**Development Flexibility:**
- NeuroTracker can be developed as a Digital Biomarker, Diagnostic or Therapeutic

**Regulatory Advantages:**
- No regulatory designation required for exploratory biomarkers

**Validation:**
- POC research completed in all 3 disease areas

**Financial Projections:**
- $3M - $5M development cost per product line
- $200M - $1.5B licensing partnership opportunity per product line

**Future Indications:**
Other indications may include Multiple Sclerosis, Autism Spectrum Disorder or Anxiety disorders (e.g. GAD, PTSD)

### Terminology:
- **DTx** = Digital Therapeutic
- **DBx** = Digital Biomarker
- **DDx** = Digital Diagnostic
- **ADHD** = Attention-Deficit/Hyperactivity Disorder
- **MCI** = Mild Cognitive Impairment
- **TBI** = Traumatic Brain Injury

---

## Slide 14: Continued Growth in Performance Markets

The continued growth in Performance sectors while launching Healthcare Division.

### Market Segments & Opportunities:

**Military & Aerospace - $5.6B**
- Chosen as the #1 cognitive solution by the U.S. Airforce to reduce the cost of training pilots and improve working memory and visual processing speed
- Subsequently signed NASA
- Key Partners: U.S. Air Force, NASA

**Health & Wellness - $206B**
- Health and Longevity organizations such as Chi Longevity and Sparks Fitness centers
- Serving high profile executives and organizations such as Four Seasons and Genesis Healthcare
- Key Partner: CHI LONGEVITY

**Education - $250B**
- Chosen by global educational institutions for cutting edge research, testing and academic improvement
- Key Partners: UC Berkeley, Texas A&M, Bengal, and Yonsei University

**Gaming - $200B**
- Selected and used by gaming organizations, academies, and esports teams
- For optimizing and developing talent, and giving their athletes the extra edge
- Key Partners: Alpine F1, Team Liquid, Kalin.ga, Complexity

**Sports - $206B**
- Used by Premier League athletes and three championship winning teams:
  1. Real Madrid (Capitals)
  2. World Series (Boston Red Sox)
  3. America Champions (Club América, Mexico)
- Key Partners: Washington Capitals, Club América

**Healthcare - $400B**
- Selected by Bayer out of 750 tech companies for cancer patients
- Investment received by UCB Pharma, with agreement to explore future licensing opportunities
- Key Partners: Bayer, UCB

**LARGE SALES PIPELINE OF PARTNERS AND CLIENTS IN EACH OF THESE SECTORS**

---

## Slide 15: Realistic & Optimistic 5-Year Revenue Projections

### Key Metrics:
- **Realistic MOIC:** 15x
- **Current Organic Growth:** 150%
- **Gross Profit Margin:** 85%

### Revenue Projections (2026-2030)

**Optimistic Scenario:**
- 2026: $11M
- 2027: $113M
- 2028: $196M
- 2029: $359M
- 2030: $594M

**Realistic Scenario:**
- 2026: $11M
- 2027: $31M
- 2028: $70M
- 2029: $140M
- 2030: $198M

### Pro-Forma Revenue Mix (2026-2030):
- Direct Revenues
- Global Licensing
- Therapeutic Licensing

### Revenue Drivers:
- Direct Revenues through B2B & B2C SaaS
- Partnerships with Snapchat, Macnica, UCB
- Discussions with Google, Apple, Oakley, Eis...
- Global Sector & Healthcare licensing deals

**Note:** Optimistic revenue scenario includes healthcare division projections

---

## Slide 16: $50M USD Series 'A' Equity Offering

### Funding Timeline & Structure

**Funding Stages:**
1. **27M USD*** - Already Invested
2. **40M USD** - Completed
3. **5M USD** - Completed
4. **50M USD** - Current Equity Raise
5. **IPO/EXIT** - Planned

### $5M 'SAFE' (Already Invested):
- **R&D, IP & Technology Development** invested from University before transfer: **$27M**

### Seed - $40M:
- Scientific and commercial validation

### Pre-Series A 'SAFE' - $5M:
- **UCB (2023)** partnership
- **Nile AI Acquired**
- Corporate Structuring

### $50M Equity Raise (Current Round - 2026):
**Series 'A' $50M (2026) Use of Funds:**
- Global Expansion
- Healthcare Sector Launch
- New Product Development
- MultiAgent AI Integration

### Future Exit:
**IPO (or Exit):** Planned in **(2029-2030)**

---

## Slide 17: Deal Comparables

### Comparable Transactions in Digital Health & Neuroscience

| The Deal | Product Bought | Outcome |
|----------|---------------|---------|
| **Eli Lilly + Karuna Therapeutics** | Schizophrenia platform | **$14B acquisition** |
| **Biogen + Reata Pharmaceuticals** | Psychiatry & neuro company | **$7.3B acquisition** |
| **Boehringer + Click** | Prescription DTx (schizophrenia) | **$960M licensing** |
| **Shionogi + Akili** | Prescription DTx (ADHD) | **$125M licensing** |
| **Otsuka** | Prescription DTx (depression) | **$302M licensing** |
| **Sword Health** | AI-powered digital health platform | **$4B valuation** |
| **Spring Health** | Digital mental health platform | **$3.3B valuation** |
| **Lyra Health** | Mental health benefits platform | **$5.8B valuation** |

**Key Insight:** The Deals span pharmaceuticals, prescription digital therapeutics, and data-driven neuro platforms — demonstrating multiple monetization paths for Neurotracker.

*References in Appendix*

---

## Slide 18: Use of Funds

### Allocation of $50M Series 'A' Funding

**Healthcare Division - 50%**
- Clinical trials, research and development
- Executive staff
- Business and partner development
- Regulatory and compliance

**Product Development - 15%**
- Focused on platform refinement, new features, and technical infrastructure

**Sales & Marketing - 25%**
- To drive customer acquisition through performance marketing, branding, and outreach

**Operations - 10%**
- Customer success
- Cloud hosting and infrastructure
- Software subscriptions
- Administrative support

**Additional Benefit:** The Canadian Government refunds up to 70% of R&D wages

---

## Slide 19: Executive Team

### Leadership Team & Advisory Board

**Jonathan Anderson** - CEO | Co Founder
- Experience: Microsoft, Bell, Cisco, CompTIA, Global Knowledge Bank

**Christina Epifano** - CSO | Co Founder
- Experience: Zimmer Biomet, Danaher

**Armando Gomez** - Co Founder
- Experience: Ziff Davis Media, IGN, News Corporation, J2, askmen

**Scott Kozak** - President
- Experience: IBM, Universal, Browne, Brown, NDIA

**Dr. Jocelyn Faubert** - Chief Science Officer | Co Founder
- Experience: Concordia, Essilor, Université de Montréal, Faubert Lab, CRSNG NSERC

**Anil Jina, MD** - Chief Medical Officer
- Experience: Pfizer, Sanofi, Shire, PPD, Akili

**Linda Assouline** - VP of Global Medical Affairs
- Experience: UCB, Abbvie, Abbott

**Sybil Dahan** - Advisor
- Experience: Aspri Pharm, Altius Healthcare, Triton, Abbott Laboratories

---

## Slide 20: Appendix

*Additional references, studies, and supporting documentation*

---

## Slide 21: Stereoscopic 3D-MOT with Speed Thresholding

### The NeuroTracker Exercise - 5 Phases

**1. Presentation**
- Homogenous spheres are presented in the 3D environment

**2. Indexation**
- Targets are revealed, then resume homogeneity

**3. Movement**
- Spheres move about the 3D space in linear paths

**4. Identification**
- Spheres cease movement and targets must be re-identified

**5. Feedback**
- Number of correctly identified targets is revealed

### Session Structure:
- Each Session is composed of **20 trials** (approx. 6 minutes)
- Each Trial takes approx. **20 seconds**

### Adaptive Closed-Loop Titration

**Adaptive Mechanism:**
- Subsequent trial speed increased/decreased as per an adaptive staircase
- Designed to maintain optimal training threshold

**Other possible adaptations:**
- Number of targets (#targets)
- Number of trials (#trials)
- Number of sessions (#sessions)
- Trial duration
- Session frequency

---

## Slide 22: NeuroTracker Creates A Unique Digital Cognitive Signature

### Research Evidence

**Study 1:** Faubert et al, Scientific Reports, 3 (2013), pp. 1-3
- Shows distinct performance curves for:
  - Professional athletes (N=102) - R² = 0.97
  - Elite amateurs (N=173) - R² = 0.98
  - Non-athletes, university (N=33) - R² = 0.97

**Study 2:** Tullo et al Res Dev Disabil 113; 2023
- Demonstrates unique cognitive signatures across populations:
  - All participants
  - ADHD
  - SLD (Specific Learning Disorder)
  - IDD (Intellectual Developmental Disorder)

### Key Capabilities:

- **Sensitive to subtle cognitive differences and changes**
- **Shows improvement ability across different populations**
- **Collects immense volume of rich data amenable to AI tools**

### Application:

NeuroTracker can be used as a **Digital Therapeutic, Diagnostic, or Biomarker**

---

## Slide 23: Large Ongoing Clinical Trial - SMARTBRAIN

### Overview

**$2M+ funded**, ongoing clinical study investigating how concussion history affects cognitive aging—and whether targeted cognitive training can measurably alter that trajectory in older adults (60+).

### Study Components:

**Biomarker Assessment in a High-Risk Population**
- **160 participants** with and without prior concussion
- Multi-modal assessments including:
  - Neuropsychological testing
  - Neurocognitive testing
  - MRI
  - Blood biomarkers
  - NeuroTracker

**Evidence of Modifiable Brain Aging Through Targeted Cognitive Training**
- **6-month NeuroTracker training** with longitudinal follow-up
- Assess durable impact on brain health and trajectories of aging

### Early Results:

**Data at 12 weeks of treatment:**
- BDNF (Brain-Derived Neurotrophic Factor) levels show significant improvement in NeuroTracker group vs Control Group
- NeuroTracker group shows consistent upward trajectory (Week 1 → Week 12)
- Control group shows minimal change or decline

**Clinical Trial Registry:** https://clinicaltrials.gov/study/NCT07025317?titles=SMARTBRAIN&rank=1

*Early Data @12 weeks treatment with NeuroTracker*

---

## Slide 24: References

### Slide 3 - Cognition at Scale

1. **99% fatigue resilience** - Prior Perceptual-Cognitive Training Builds Mental Resistance During Acute Physical Fatigue In Professional Rugby Athletes, ResearchGate
2. **52% perception, 34% cognitive agility, 34% peripheral vision** - Perceptual-Cognitive Training with the NeuroTracker 3D-MOT to Improve Performance in Three Different Sports, Apunts Sports Training
3. **40% decision-making** - 3D-Multiple Object Tracking Task Performance Improves Passing Decision-Making Accuracy in Soccer Players, Psychology of Sport and Exercise
4. **40% focus** - Off-Court Generic Perceptual-Cognitive Training in Elite Volleyball Athletes: Task-Specific Effects and Levels of Transfer, Frontiers in Psychology

### Slide 8 - 120+ Studies & Trials on NeuroTracker

1. 3D Multiple Object Tracking Boosts Working Memory Span: Implications for Cognitive Training in Military Populations - Oshin Vartanian, Lori Coady & Kristen Blackler. Military Psychology, Volume 28, 2016 - Issue 5
2. Transferability of Multiple Object Tracking Skill Training to Professional Baseball Players' Hitting Performance - Ryousuke Furukado et al. Journal Of Digital Life. 2024, 4, S5
3. Effect of 3D-Multiple Object Tracking Training on Manual Dexterity in Elderly Adults with Dementia and Mild Cognitive Impairment - Angel Ferris Vizcarra et al. Rhythms in Healthcare
4. Effects of 3D-Multiple Object Tracking on Reaction Time Performance in High-Performance Varsity Swimmers - Snowden TM et al. Journal of Athletic Enhancement Vol: 9 Issue: 1
5. 3D-Multiple Object Tracking task performance improves passing decision-making accuracy in soccer players - Thomas Romeas, Antoine Guldner, Jocelyn Faubert
6. Enhancing Cognitive Function Using Perceptual-Cognitive Training - Brendan Parsons at Clinical Trials and Clinical Neuroscience
7. Comprehensive pre-post neuropsychological and qEEG neuroimaging assessments reveal robust and wide gains in college students' cognitive abilities - Nutrition, lifestyle, and cognitive performance in esport athletes - Jenna Blair Goulart et al. Frontiers in Nutrition
8. 3-Dimensional Multiple Object Tracking Training Can Enhance Selective Attention, Psychomotor Speed, and Cognitive Flexibility in Healthy Older Adults - Brian R Christie. Ageing Science & Mental Health Studies

### Slide 17 - Deal Comparables

1. Eli Lilly acquisition (Karuna Therapeutics, ~$14B) - https://www.pharmaceutical-technology.com/news/eli-lilly-karuna-therapeutics-acquisition/
2. AbbVie acquisition (Cerevel Therapeutics, ~$8.7B) - https://www.pharmaceutical-technology.com/news/abbvie-cerevel-therapeutics/
3. Biogen acquisition (Reata Pharmaceuticals, ~$7.3B) - https://www.fiercebiotech.com/biotech/biogen-buy-reata-pharmaceuticals-73b
4. Boehringer Ingelheim licensing deal (Click Therapeutics, ~$960M) - https://pharmaphorum.com/news/click-bags-fda-breakthrough-tag-schizophrenia-dtx
5. Shionogi + Akili - https://www.shionogi.com/content/dam/shionogi/global/news/pdf/2019/e_190307.pdf
6. Otsuka licensing deal (Click Therapeutics, ~$302M) - https://firstwordpharma.com/story/5174912
7. Sword Health valuation ($4B) - https://techcrunch.com/2025/06/17/sword-health-nabs-40m-at-4b-valuation-pushes-ipo-plans-to-at-least-2028/
8. BetterUp valuation ($4.7B) - https://www.betterup.com/press/series-e
9. Spring Health valuation ($3.3B) - https://fortune.com/2024/07/31/spring-health-valuation-ai-mental-health-april-koh/
10. Lyra Health valuation ($5.8B) - https://getlatka.com/companies/lyra-health
11. Johnson & Johnson acquisition (Intra-Cellular Therapies, ~$14.6B) - https://synapse.patsnap.com/article/jj-boosts-neuroscience-with-146bn-intra-cellular-buyout

---

## Slide 25: Thank You

### Contact Information

**Website:**
- neurotrackerx.com
- nothingartificial.ai

**Email Address:**
- janderson@nothin... (contact information)

---

*This document represents the complete 25-slide NeuroTracker presentation*
